



August 1, 2017

Aquinox Pharmaceuticals to Announce Second Quarter 2017 Financial Results

Conference call Tuesday August 8, 2016 at 8:30 AM ET

VANCOUVER, British Columbia, Aug. 01, 2017 (GLOBE NEWSWIRE) -- [Aquinox Pharmaceuticals, Inc.](#) ("[Aquinox](#)") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, will report its financial results for the second quarter ending June 30, 2017 and will provide a general business update on Tuesday, August 8, 2017 before U.S. markets open. [Aquinox](#)'s management will also host a conference call and live audio webcast on Tuesday, August 8, 2017 at 8:30 AM (ET) / 5:30 AM (PT).

Conference Call and Webcast Details:

Date: Tuesday, August 8th, 2017
Time: 8:30 AM (ET) / 5:30 AM (PT)
Toll-free: (866) 357-7878
International: (315) 625-3088
Conference ID: 59711876
Webcast URL: <http://edge.media-server.com/m/p/mqa4bkna>

The live webcast may be accessed through the "[Events & Presentations](#)" page in the "[Investor Relations](#)" section of the company's website at www.aqxpharma.com.

The archived webcast will also be available on [Aquinox](#)'s website approximately two hours after the event and will be available for replay for at least 30 days after the event.

About [Aquinox Pharmaceuticals, Inc.](#)

Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.

Investor Contact Info:

Brendan Payne Associate Director, Investor Relations Aquinox Pharmaceuticals, Inc. 604.901.3019 ir@aqxpharma.com	Gitanjali Ogawa Vice President The Trout Group 646-378-2949 Gogawa@troutgroup.com
---	---

 Primary Logo

Source: Aquinox Pharmaceuticals, Inc.

News Provided by Acquire Media